Latest Capital Markets News

Tartana Minerals has lodged a cleansing prospectus to enable ASX quotation of over 129 million options linked to a $4.5 million placement, with exercise price set at 5.5 cents and expiry in April 2029.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.

Green & Gold Minerals posted a $886,828 loss for FY2026 amid a transformative year marked by its ASX listing and expansion into base metals exploration with the Herberton acquisition.

Almasar Minerals Limited (ASX:AMK) is launching an IPO to fund early-stage exploration across five licences in Saudi Arabia’s Arabian Shield, targeting gold and copper mineralisation.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

Careteq Limited (ASX: CTQ) reported a $398K net loss for FY26 amid a strategic reset that included selling its Embedded Health Solutions business and repaying all debt. The company now pivots fully to growing its HMR Referrals platform with $3.19 million cash on hand.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Ingenia Communities Group has unveiled a $2.185 per share acquisition offer for Peet Limited, aiming to create Australia’s largest pure-play living sector platform with enhanced scale, diversification, and market presence.

Stakk is on the cusp of completing its US$63 million acquisition of ParaScript, having secured shareholder approval and completed a A$27 million placement. The combined entity is poised to meet or exceed FY2027 revenue and EBITDA targets, reinforcing its digital trust platform strategy.

Resimac Group Ltd delivered a 42% jump in statutory profit for FY26 despite flat revenue, driven by strong home loan growth and improved margins, while raising its final dividend to 6 cents per share.

L1 Global Long Short Fund (ASX:GLS) reported a striking $121.3 million net profit for FY26 following its strategic reset, declaring a fully franked 2.00 cent final dividend and targeting 8.00 cents per share for FY27.